Exploring cellular diversity in lung adenocarcinoma epithelium: Advancing prognostic methods and immunotherapeutic strategies

Abstract

Immunotherapy has brought significant advancements in the treatment of lung adenocarcinoma (LUAD), but identifying suitable candidates remains challenging. In this study, we investigated tumour cell heterogeneity using extensive single-cell data and explored the impact of different tumour cell cluster abundances on immunotherapy in the POPLAR and OAK immunotherapy cohorts. Notably, we found a significant correlation between CKS1B+ tumour cell abundance and treatment response, as well as stemness potential. Leveraging marker genes from the CKS1B+ tumour cell cluster, we employed machine learning algorithms to establish a prognostic and immunotherapeutic signature (PIS) for LUAD. In multiple cohorts, PIS outperformed 144 previously published signatures in predicting LUAD prognosis. Importantly, PIS reliably predicted genomic alterations, chemotherapy sensitivity and immunotherapy responses. Immunohistochemistry validated lower expression of immune markers in the low-PIS group, while in vitro experiments underscored the role of the key gene PSMB7 in LUAD progression. In conclusion, PIS represents a novel biomarker facilitating the selection of suitable LUAD patients for immunotherapy, ultimately improving prognosis and guiding clinical decisions.

References

[1] ChenS, CaoZ, PrettnerK, et al. Estimates and projections of the global economic cost of 29 cancers in 204 countries and territories from 2020 to 2050. JAMA Oncol. 2023;9(4):465-472.

[2] BrodyH. Lung cancer. Nature. 2020;587(7834):S7.

[3] SungH, FerlayJ, SiegelRL, et al. Global cancer statistics 2020:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;3:209-249.

[4] ChenZ, Fillmore CM, HammermanPS, KimCF, WongK-K. Non-small-cell lung cancers: a heterogeneous set of diseases. Nat Rev Cancer. 2014;14(8):535-546.

[5] HirschFR, Scagliotti GV, MulshineJL, et al. Lung cancer: current therapies and new targeted treatments. Lancet. 2017;389(10066):299-311.

[6] ConroyM, FordePM. Advancing neoadjuvant immunotherapy for lung cancer. Nat Med. 2023;29(3):533-534.

[7] DuffyMJ, CrownJ. Biomarkers for predicting response to immunotherapy with immune checkpoint inhibitors in cancer patients. Clin Chem. 2019;65(10):1228-1238.

[8] WuF, FanJ, HeY, et al. Single-cell profiling of tumor heterogeneity and the microenvironment in advanced non-small cell lung cancer. Nat Commun. 2021;12(1):2540.

[9] HuZ, JinX, HongW, et al. Dissecting the single-cell transcriptome network of macrophage and identifies a signature to predict prognosis in lung adenocarcinoma. Cell Oncol. 2023;46(5):1351-1368.

[10] ZhangJ, LiuX, HuangZ, et al. T cell-related prognostic risk model and tumor immune environment modulation in lung adenocarcinoma based on single-cell and bulk RNA sequencing. Comput Biol Med. 2023;152:106460.

[11] ZhangZ, ZhuH, WangX, Lin S, RuanC, WangQ. A novel basement membrane-related gene signature for prognosis of lung adenocarcinomas. Comput Biol Med. 2023;154:106597.

[12] SalcherS, SturmG, HorvathL, et al. High-resolution single-cell atlas reveals diversity and plasticity of tissue-resident neutrophils in non-small cell lung cancer. Cancer Cell. 2022;40(12):1503-1520.e8.

[13] TomidaS, Takeuchi T, ShimadaY, et al. Relapse-related molecular signature in lung adenocarcinomas identifies patients with dismal prognosis. J Clin Oncol. 2009;27(17):2793-2799.

[14] WilkersonMD, YinX, WalterV, et al. Differential pathogenesis of lung adenocarcinoma subtypes involving sequence mutations, copy number, chromosomal instability, and methylation. PLoS One. 2012;7(5):e36530.

[15] StaafJ, Jönsson G, JönssonM, et al. Relation between smoking history and gene expression profiles in lung adenocarcinomas. BMC Med Genet. 2012;5:22.

[16] RousseauxS, Debernardi A, JacquiauB, et al. Ectopic activation of germline and placental genes identifies aggressive metastasis-prone lung cancers. Sci Transl Med. 2013;5(186):186ra66.

[17] OkayamaH, KohnoT, IshiiY, et al. Identification of genes upregulated in ALK-positive and EGFR/KRAS/ALK-negative lung adenocarcinomas. Cancer Res. 2012;72(1):100-111.

[18] TangH, XiaoG, BehrensC, et al. A 12-gene set predicts survival benefits from adjuvant chemotherapy in non-small cell lung cancer patients. Clin Cancer Res. 2013;19(6):1577-1586.

[19] RittmeyerA, Barlesi F, WaterkampD, et al. Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK):a phase 3, open-label, multicentre randomised controlled trial. Lancet. 2017;389(10066):255-265.

[20] FehrenbacherL, SpiraA, BallingerM, et al. Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR):a multicentre, open-label, phase 2 randomised controlled trial. Lancet. 2016;387(10030):1837-1846.

[21] CaoY, FuL, WuJ, et al. Integrated analysis of multimodal single-cell data with structural similarity. Nucleic Acids Res. 2022;50(21):e121.

[22] GulatiGS, Sikandar SS, WescheDJ, et al. Single-cell transcriptional diversity is a hallmark of developmental potential. Science. 2020;367(6476):405-411.

[23] WuY, YangS, MaJ, et al. Spatiotemporal immune landscape of colorectal cancer liver metastasis at single-cell level. Cancer Discov. 2022;12(1):134-153.

[24] JewB, Alvarez M, RahmaniE, et al. Accurate estimation of cell composition in bulk expression through robust integration of single-cell information. Nat Commun. 2020;11(1):1971.

[25] HänzelmannS, Castelo R, GuinneyJ. GSVA: gene set variation analysis for microarray and RNA-seq data. BMC Bioinformatics. 2013;14:7.

[26] MayakondaA, LinDC, AssenovY, Plass C, KoefflerHP. Maftools: efficient and comprehensive analysis of somatic variants in cancer. Genome Res. 2018;28(11):1747-1756.

[27] YoshiharaK, Shahmoradgoli M, MartínezE, et al. Inferring tumour purity and stromal and immune cell admixture from expression data. Nat Commun. 2013;4:2612.

[28] Meric-BernstamF, LarkinJ, TaberneroJ, Bonini C. Enhancing anti-tumour efficacy with immunotherapy combinations. Lancet. 2021;397(10278):1010-1022.

[29] VoelkerR. Immunotherapy approved for endometrial cancer. J Am Med Assoc. 2021;325(21):2143.

[30] BossiP, Gurizzan C, ChanA. Immunotherapy for nasopharyngeal carcinoma: the earlier the better. J Am Med Assoc. 2023;330(20):1954-1955.

[31] LovlyCM. Perioperative immunotherapy—a KEY toward improved outcomes for early-stage lung cancer? New Engl J Med. 2023;389(6):560-561.

[32] McKayRR. The promise of adjuvant immunotherapy in renal-cell carcinoma. New Engl J Med. 2021;385(8):756-758.

[33] CrunkhornS. Improving immunotherapy. Nat Rev Drug Discov. 2020;19(2):92.

[34] BeattyGL, Gladney WL. Immune escape mechanisms as a guide for cancer immunotherapy. Clin Cancer Res. 2015;21(4):687-692.

[35] DuttaAK, Alberge JB, Sklavenitis-PistofidisR, LightbodyED, Getz G, GhobrialIM. Single-cell profiling of tumour evolution in multiple myeloma -opportunities for precision medicine. Nat Rev Clin Oncol. 2022;19(4):223-236.

[36] GohilSH, Iorgulescu JB, BraunDA, KeskinDB, LivakKJ. Applying high-dimensional single-cell technologies to the analysis of cancer immunotherapy. Nat Rev Clin Oncol. 2021;18(4):244-256.

[37] WangH, ZhangZ, YanZ, MaS. CKS1B promotes cell proliferation and invasion by activating STAT3/PD-L1 and phosphorylation of Akt signaling in papillary thyroid carcinoma. J Clin Lab Anal. 2021;35(1):e23565.

[38] WangX, TaoG, HuangD, Liang S, ZhengD. Circular RNA NOX4 promotes the development of colorectal cancer via the microRNA-485-5p/CKS1B axis. Oncol Rep. 2020;44(5):2009-2020.

[39] LiuX, ZhaoD. CKS1B promotes the progression of hepatocellular carcinoma by activating JAK/STAT3 signal pathway. Anim Cells Syst. 2021;25(4):227-234.

[40] HwangJS, JeongEJ, ChoiJ, et al. MicroRNA-1258 inhibits the proliferation and migration of human colorectal cancer cells through suppressing CKS1B expression. Genes. 2019;10(11):912.

[41] LiL, WangJ, ZhangZ, et al. Identification of CKS1B as a prognostic indicator and a predictive marker for immunotherapy in pancreatic cancer. Front Immunol. 2022;13:1052768.

[42] KyrychenkoVO, Nagibin VS, TumanovskaLV, et al. Knockdown of PSMB7 induces autophagy in cardiomyocyte cultures: possible role in endoplasmic reticulum stress. Pathobiology. 2014;81(1):8-14.

[43] WuD, MiaoJ, HuJ, et al. PSMB7 is a key gene involved in the development of multiple myeloma and resistance to bortezomib. Front Oncol. 2021;11:684232.

[44] MunkácsyG, Abdul-Ghani R, MihályZ, et al. PSMB7 is associated with anthracycline resistance and is a prognostic biomarker in breast cancer. Br J Cancer. 2010;102(2):361-368.

RIGHTS & PERMISSIONS

2024 The Author(s). Cell Proliferation published by Beijing Institute for Stem Cell and Regenerative Medicine and John Wiley & Sons Ltd.